Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr;105(4):332-338.
doi: 10.1136/archdischild-2019-317910. Epub 2019 Sep 4.

Mortality and respiratory support in X-linked myotubular myopathy: a RECENSUS retrospective analysis

Robert J Graham  1 , Francesco Muntoni  2 , Imelda Hughes  3 , Sabrina W Yum  4 , Nancy L Kuntz  5 , Michele L Yang  6 , Barry J Byrne  7 , Suyash Prasad  8 , Rachel Alvarez  9 , Casie A Genetti  10 , Tmirah Haselkorn  11 , Emma S James  8 , Laurie B LaRusso  12 , Mojtaba Noursalehi  8 , Salvador Rico  8 , Alan H Beggs  13
Affiliations

Mortality and respiratory support in X-linked myotubular myopathy: a RECENSUS retrospective analysis

Robert J Graham et al. Arch Dis Child. 2020 Apr.

Abstract

Purpose: Individuals with X-linked myotubular myopathy (XLMTM) who survive infancy require extensive supportive care, including ventilator assistance, wheelchairs and feeding tubes. Half die before 18 months of age. We explored respiratory support and associated mortality risk in RECENSUS, particularly among patients ≤5 years old who received respiratory support at birth; this subgroup closely matches patients in the ASPIRO trial of gene therapy for XLMTM.

Design: RECENSUS is an international, retrospective study of patients with XLMTM. Descriptive and time-to-event analyses examined survival on the basis of age, respiratory support, tracheostomy use, predicted mutational effects and life-sustaining care.

Results: Outcomes for 145 patients were evaluated. Among 126 patients with respiratory support at birth, mortality was 47% overall and 59% among those ≤5 years old. Median survival time was shorter for patients ≤5 years old than for those >5 years old (2.2 years (IQR 0.7-5.6) vs 30.2 years (IQR 19.4-30.2)). The most common cause of death was respiratory failure (66.7%). Median survival time was longer for patients with a tracheostomy than for those without (22.8 years (IQR 8.7-30.2) vs 1.8 years (IQR 0.2-not estimable)). The proportion of patients living without a tracheostomy was 50% at age 6 months and 28% at age 2 years. Median survival time was longer with provision of life-sustaining care than without (19.4 years (IQR 3.1-not estimable) vs 0.2 years (IQR 0.1-2.1)).

Conclusions: High mortality, principally due to respiratory failure, among patients with XLMTM ≤5 years old despite respiratory support underscores the need for early diagnosis, informed decision-making and disease-modifying therapies.

Trial registration number: NCT02231697.

Keywords: X-linked myotubular myopathy; centronuclear myopathy; congenital myopathy; mortality; respiratory support; retrospective chart review; tracheostomy.

PubMed Disclaimer

Conflict of interest statement

Competing interests: RJG, IH, MLY, NLK and SWY report no conflicts of interest with respect to this study. RJG is an unpaid member of Audentes Therapeutics Board of Scientific and Clinical Advisors. RA is a volunteer for Cure CMD and has no financial interest in Audentes or related to this study. LBL received financial compensation for medical writing, and TH is a consultant to Audentes Therapeutics. ESJ, MN, SR and SP are employees and shareholders of Audentes Therapeutics. AHB is a member of the Audentes Therapeutics Board of Scientific and Clinical Advisors and has received support from a sponsored research agreement with Audentes Therapeutics to cover running costs for this study.

Figures

Figure 1
Figure 1
Kaplan-Meier analyses. (A) Time to death by age (≤5 vs >5 years) for patients who required respiratory support at birth. (B) Time to death by mutation class. (C) Time to death by tracheostomy status.
Figure 2
Figure 2
Withdrawal of life-sustaining support. (A) Kaplan-Meier analysis of time to death by whether life-sustaining support was withdrawn or maintained. (B) Age at which life-sustaining support was withdrawn (n=16).
See this image and copyright information in PMC

References

    1. Dowling JJ, Lawlor MW, Das S. X-Linked Myotubular Myopathy : Adam MP, Ardinger HH, Pagon RA, GeneReviews((R))1993-2019. Seattle (WA), 2002.
    1. Hnia K, Vaccari I, Bolino A, et al. . Myotubularin phosphoinositide phosphatases: cellular functions and disease pathophysiology. Trends Mol Med 2012;18:317–27. 10.1016/j.molmed.2012.04.004 - DOI - PubMed
    1. Jungbluth H, Wallgren-Pettersson C, Laporte J. Centronuclear (myotubular) myopathy. Orphanet J Rare Dis 2008;3:26 10.1186/1750-1172-3-26 - DOI - PMC - PubMed
    1. Vandersmissen I, Biancalana V, Servais L, et al. . An integrated modelling methodology for estimating the prevalence of centronuclear myopathy. Neuromuscul Disord 2018;28:766–77. 10.1016/j.nmd.2018.06.012 - DOI - PubMed
    1. Herman GE, Kopacz K, Zhao W, et al. . Characterization of mutations in fifty North American patients with X-linked myotubular myopathy. Hum Mutat 2002;19:114–21. 10.1002/humu.10033 - DOI - PubMed

Publication types

Associated data

LinkOut - more resources